Progressive plasticity during colorectal cancer metastasis

Andrew R Moorman(Memorial Sloan Kettering Cancer Center), Elizabeth K. Benitez(Memorial Sloan Kettering Cancer Center), Francesco Cambulli(Memorial Sloan Kettering Cancer Center), Qingwen Jiang(Memorial Sloan Kettering Cancer Center), Ahmed Mahmoud(Memorial Sloan Kettering Cancer Center), Melissa Lumish(Memorial Sloan Kettering Cancer Center), Saskia Hartner(Memorial Sloan Kettering Cancer Center), Sandy Balkaran(Memorial Sloan Kettering Cancer Center), Jonathan Bermeo(Memorial Sloan Kettering Cancer Center), Simran Asawa(Memorial Sloan Kettering Cancer Center), Canan Firat(Memorial Sloan Kettering Cancer Center), Asha Krishnan(Memorial Sloan Kettering Cancer Center), Fan Wu(Memorial Sloan Kettering Cancer Center), Anisha Luthra(Memorial Sloan Kettering Cancer Center), Cassandra Burdziak(Memorial Sloan Kettering Cancer Center), Yubin Xie(Memorial Sloan Kettering Cancer Center), Valeria Sgambati(Memorial Sloan Kettering Cancer Center), Kathleen Luckett(Memorial Sloan Kettering Cancer Center), Yun Li(Memorial Sloan Kettering Cancer Center), Zhengjun Yi(Memorial Sloan Kettering Cancer Center), Ignas Masilionis(Memorial Sloan Kettering Cancer Center), Kevin C. Soares(Memorial Sloan Kettering Cancer Center), Emmanouil P. Pappou(Memorial Sloan Kettering Cancer Center), Rona Yaeger(Memorial Sloan Kettering Cancer Center), T. Peter Kingham(Memorial Sloan Kettering Cancer Center), William R. Jarnagin(Memorial Sloan Kettering Cancer Center), Philip B. Paty(Memorial Sloan Kettering Cancer Center), Martin R. Weiser(Memorial Sloan Kettering Cancer Center), Linas Mažutis(Memorial Sloan Kettering Cancer Center), M.I. D’Angelica(Memorial Sloan Kettering Cancer Center), Jinru Shia(Memorial Sloan Kettering Cancer Center), Julio García‐Aguilar(Memorial Sloan Kettering Cancer Center), Tal Nawy(Memorial Sloan Kettering Cancer Center), T. J. Hollmann(Memorial Sloan Kettering Cancer Center), Ronan Chaligné(Memorial Sloan Kettering Cancer Center), Francisco Sánchez-Vega(Memorial Sloan Kettering Cancer Center), Roshan Sharma(Memorial Sloan Kettering Cancer Center), Dana Pe’er(Howard Hughes Medical Institute), Karuna Ganesh(Memorial Sloan Kettering Cancer Center)
Nature
October 30, 2024
Cited by 141Open Access
Full Text

Abstract

Abstract As cancers progress, they become increasingly aggressive—metastatic tumours are less responsive to first-line therapies than primary tumours, they acquire resistance to successive therapies and eventually cause death 1,2 . Mutations are largely conserved between primary and metastatic tumours from the same patients, suggesting that non-genetic phenotypic plasticity has a major role in cancer progression and therapy resistance 3–5 . However, we lack an understanding of metastatic cell states and the mechanisms by which they transition. Here, in a cohort of biospecimen trios from same-patient normal colon, primary and metastatic colorectal cancer, we show that, although primary tumours largely adopt LGR5 + intestinal stem-like states, metastases display progressive plasticity. Cancer cells lose intestinal cell identities and reprogram into a highly conserved fetal progenitor state before undergoing non-canonical differentiation into divergent squamous and neuroendocrine-like states, a process that is exacerbated in metastasis and by chemotherapy and is associated with poor patient survival. Using matched patient-derived organoids, we demonstrate that metastatic cells exhibit greater cell-autonomous multilineage differentiation potential in response to microenvironment cues compared with their intestinal lineage-restricted primary tumour counterparts. We identify PROX1 as a repressor of non-intestinal lineage in the fetal progenitor state, and show that downregulation of PROX1 licenses non-canonical reprogramming.


Related Papers